Commentary on the NIH Consensus Development Statement(1) from the Meeting on November 17-19, 1997 Effective Medical Treatment of Heroin Addiction

The National Alliance of Methadone Advocates supports the NIH Consensus
Statement on Effective Treatment of Heroin Addiction that was facilitated by the
National Institute on Drug Abuse and the National Institute of Health.

The imprecate of this special statement should be understood in order to
realize the impact that it can have on methadone maintenance treatment. The
Consensus Statements are prepared by a special committee who are comprised of
individuals who are typically professionals from the disciplines involved in the
issue (i.e. doctors, lawyers, etc.) but they have no connections to the field
being examined. In this respect their conclusions are independent and thus
greater influence. The prepared statement is based on the (1) presentations from
panels consisting of professionals working in the field and relevant areas; (2)
questions and statements from conference attendees during open discussion
periods that are part of the public session; and (3) closed deliberations by The
Committee. Thus the statement is an independent report of the consensus panel
and is not a policy statement of the NIH or the Federal Government.

A Summary of the Recommendations are:

  1. Strong leadership is necessary in educating the public that addiction is
    not self inflicted but is a medical disorder that includes a spectrum of
    brain and medical conditions that can be effectively treated with benefits
    to society.

  2. Society needs to make a commitment to offer effective treatment for heroin
    addiction for all who need it.

  3. Opiate-addicted persons under legal supervision need to have access to
    methadone maintenance treatment.

  4. The training of physicians and other health care professionals need
    improvement regarding the diagnosis and treatment of opiate addiction.

  5. The unwarranted over regulation of methadone maintenance treatment and all
    opiate agonist treatment programs needs to be reduced.

  6. Funding for methadone maintenance treatment needs to be increased and
    required as a benefit for public and private insurance programs equivalent
    to the coverage for all medical and mental disorders.

  7. Chemically dependent pregnant women need to receive special consideration
    and methadone maintenance treatment must be culturally sensitive to enhance
    favorable outcomes for participating African American and Hispanic persons.

  8. Patients, underrepresented minorities, and consumers should be included in
    bodies charged with policy development guiding opiate addiction treatment.

  9. Methadone maintenance treatment needs to be expanded within States and
    regions where programs where it is currently unavailable.

Summary

The Consensus Committee in their full statement emphasized the rigorous
scientific studies that methadone maintenance had undergone over the past 30
years that demonstrate its effectiveness in significantly lowering illicit
opiate drug use, reducing illness and death from illicit opiate drug use,
reducing crime, and by enhancing social productivity. And that in order for
methadone maintenance treatment to receive adequate funding and it’s expansion
be supported it will be necessary to undertake a campaign to educate
politicians, policy makers and society that opiate addiction is a medical
disorder and methadone is effective in treating it.

To replace the regulations The Committee recommended alternatives such as
physician accreditation and certification and to improve education that
physicians, nurses and other health professionals receive. While reducing
regulations will help to promote expansion of methadone maintenance treatment
increased funding is necessary to ensure expansion in all states including those
that do not currently provide it. The Committee strongly recommended that
legislators and regulators recognize the cost effectiveness of methadone
maintenance treatment and that benefits for treatment be part of public and
private insurance programs.

Bodies charged with policy The Committee urged should be include
misrepresented minorities and patients. The Committee stressed that methadone
treatment must be culturally sensitive and that risk groups, such as pregnant
women should be targeted.

What Can Advocates Do?

It is now important for us to ensure that the conclusion of this Consensus
Statement become known by politicians and policy makers. Patients and the family
members of patients should write to their representatives and tell them that
methadone maintenance treatment does work and most important that it saves ad
restores lives. Do not stop at the federal and national level continue writing
and talking with state and local politicians and policy makers. Because
methadone maintenance treatment has been politicized it is at that level that
must first be education. This Consensus Statements give us the chance to promote
and influence the medicalization of methadone maintenance treatment.




1. Effective Medical
Treatment of Heroin Addiction
. NIH Consensus Statement 1997 November
17-19;15(6). Available from the National
Clearinghouse for Alcohol and Drug Information
NCADI


Similar Posts

  • Federal Regulations & Accreditation Resources

    Admin 08/24/2021

    Federal Regulations & Documents Code of Federal Regulations. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Final Rule 21 CRF 291, 42 CRF 8. (Text) Federal Regulations (PDF Format) . Code of Federal Regulations. Confidentiality of Alcohol and Drug Abuse Patient Records (PDF Format). CSAT Accreditation Page. CSAT Guidelines for the accreditation of…

  • Focus On

    Admin 09/16/2021

    Issues To Focus On LAAM Manufacture to Be Discontinued August 23, 2003 Washington, D.C. Roxanne the manufacturer of LAAM has informed the FDA that manufacture of the medication is being discontinued. Distribution will continue until the inventory is depleted. Roxanne estimates this to be in early January 2004. The reason for the action is the…

  • Sample Letter

    Admin 04/08/2021

    ________________________________ Your Name ________________________________ Address ________________________________ City, State, Zip Date____________________________         Honorable Senator  ________________ United States Senate Washington, DC  20515 Dear Senator _____________________: On February 11, 1999 Senator McCain introduced S423 the Addiction Free Treatment Act. This legislation was intended as a political assault on the Office of National Drug Control Policy…

  • NAMA Affiliates Pages

    Admin 10/23/2022

    Affiliates Package The first 2 parts of the Affiliates Package are in Ebook format. This means that your computer sees the file as an application and it will have an “exe” file extension. If you click on the file like it is an application – the Ebook with the documents will open. You can then…

  • How Methadone Works by Joycelyn Woods

    Admin 06/24/2021

    National Alliance of Methadone Advocates The Pharmacology of Methadone Ignorance about methadone abounds. Professionals working in the field receive very little or no training at all about the very medication that they will be administering. Rarely is addiction viewed as a disease and under the domain of the medical profession. Even the medical profession does…

  • Pharmacological Agents Interacting With Methadone

    Admin 09/10/2021

    Information on NAMA’s website is not intended as medical advice for individual problems.   Appropriate medical professionals should be consulted regarding addiction and addiction recovery.   Pharmacologic Agents Clinical Signs and Symptoms Comments Drugs That Decrease Methadone Levels Rifampin, phenytoin, carbamazepine, butabarbital sodium, mephobarbital, phenobarbital, secobarbital, ethanol (chronic), disulfiram, urinary acidifiers, ascorbic acid Withdrawal signs Disulfiram…